Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
Read More
1 minute read

RenovoRx Announces Publication Of Results Of Pre-Clinical Studies Support Efficacy And Drug Delivery Mechanism Potential Of The Co’s TAMP Therapy Platform To Improve Targeted Cancer Drug Treatment Delivery

By Benzinga Newsdesk
May 21, 9:36 AM
Data shows that the Trans-Arterial Micro-Perfusion (TAMP) platform increases intra-arterial pressure, improving drug delivery with 100-fold increase local tissue concentration of the therapyTAMP offers the potential to

RNXT

Read More
2 minute read

Alibaba Sparks AI Price War With Massive Discounts: Report

By Shivani Kumaresan
May 21, 9:23 AM
Alibaba Group (NYSE:BABA) has drastically cut prices on its AI services by up to 97%, sparking a fierce price war in China's burgeoning AI sector. Competitors Baidu (NASDAQ:BIDU) and ByteDance have swiftly responded with aggressive pricing and free services. This competition highlights the intense race among Chinese tech giants, including Tencent, to dominate the AI market, fueled by massive investments and strategic restructuring efforts.

BABA

Read More
1 minute read

Biodexa Pharmaceuticals Presents Phase 2 Clinical Trial Results Of Its Newly-Licensed eRapa In Familial Adenomatous Polyposis Scheduled For Presentation At The 2024 Digestive Disease Week Annual Meeting; Reports Overall 83% Non-Progression Rate At 6 Mo…

By Benzinga Newsdesk
May 21, 8:38 AM
Biodexa Pharmaceuticals PLC("Biodexa" or the "Company")Positive Statistically Significant Phase 2 Clinical Trial Results of Biodexa's Newly-licensed eRapa™ in Familial Adenomatous Polyposis (FAP) Scheduled for

BDRX

Read More
2 minute read

Macy’s Q1 Surprises With Profit Beat And Upgraded Outlook Amid Sales Challenges – Here’s The Scoop

By Shivani Kumaresan
May 21, 8:37 AM
Macy's shares are climbing after reporting better-than-expected Q1 adjusted EPS and raising its FY24 outlook. Despite a 2.7% year-on-year sales decline to $4.846 billion, Macy's adjusted EPS of $0.27 beat the $0.15 consensus. The company updated its FY24 sales forecast to $22.3B-$22.9B and adjusted EPS guidance to $2.55-$2.90, reflecting strong customer response to their new strategy.

M